Archive for September 2019
New bio-engineering accelerator wants to offer startups ‘unfair advantage’
Seaport-based Petri will offer entrepreneurs and startups office and laboratory space, $250,000 or more in equity financing and access to a network of industry experts. Read More
Read MoreHere’s advice from patent attorneys for innovators
The Business Journal asked three intellectual property lawyers about industry demand and advice for innovators. Read More
Read MoreFive things you need to know today, and a Friday the 13th harvest moon
Good morning, everyone. Here are the five most important things you need to know to get your Friday the 13th started, plus some Friday fun facts and more. Read More
Read MoreHarvard president says school received $9M from Epstein
Harvard University broke its silence and said it received about $9 million in donations from Jeffrey Epstein. Read More
Read MoreCannabis testing lab fined $225K for leaving weed waste in dumpster
The Cannabis Control Commission has fined a Framingham cannabis lab $225,000 over allegedly improperly disposing of cannabis. Read More
Read MoreMIT president admits signing 2012 acknowledgement of Epstein gift
MIT released a preliminary update just three days after the school hired the law firm Goodwin Procter to investigate donations from the late billionaire and convicted sex offender Jeffrey Epstein. Read More
Read MoreLongtime Boston planning dept. employee pleads guilty in federal bribery case
John M. Lynch could face between 46 and 57 months in prison. Read More
Read MoreWS Development pitches change in building use in Boston’s Seaport District
The real-estate company said it plans a shift in use of a Seaport District building. Read More
Read MoreYoung blood for old money: Many Boston-area financial advisers lack succession plans
Many of Greater Boston’s financial planners and advisers don’t have succession plans. It’s a problem for some, an opportunity for others. Read More
Read MoreVertex strikes deal to sell cystic fibrosis drugs in Scotland, but British debate continues
While Vertex’s drug pricing battle with British regulators continues, it has made advances abroad, signing a deal this week to make two of its cystic fibrosis drugs available in Scotland. Read More
Read More